U.S. Markets closed

Innoviva, Inc. (INVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
13.78+0.29 (+2.15%)
At close: 4:00PM EDT
People also watch
TBPHDERMITCINEOSIRWD

Innoviva, Inc.

2000 Sierra Point Parkway
Suite 500
Brisbane, CA 94005
United States
650-238-9600
http://www.inva.com

SectorTechnology
IndustryApplication Software
Full Time Employees13

Key Executives

NameTitlePayExercisedAge
Mr. Michael W. AguiarChief Exec. Officer, Pres and Director1.44MN/A51
Mr. Eric d'EsparbesChief Financial Officer and Sr. VP686.28kN/A49
Dr. Theodore J. Witek Jr., MBA, Ph.D.Chief Scientific Officer and Sr. VP696.7kN/A59
Mr. Michael Eric FaermChief Bus. Officer and Sr. VP869.01kN/A50
Mr. Jeffrey A. Hagenah Ph.D.Chief Patent Counsel and VPN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components. It has LABA collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.

Corporate Governance

Innoviva, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 4. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.